|
|
 |
|
Viewing report
|
|
|
|
World Cancer Assay Markets
Frost & Sullivan, Oct 2001
Cancer Assays Pave Way for Hybridization Technology's Success
The field of cancer assays has evolved tremendously over the years, with focus shifting from immunoassays to assessing the genetic basis of cancer. Immunoassays detect the presence of tumor markers secreted by cancer cells and operate on the premise of an antibody identifying an analyte as its antigen. Hybridization technology is now being applied to the identification of
mutations responsible for cancer development. Widespread adoption is forecast, as this technology becomes increasingly reliable as a means of cancer evaluation.
This Frost & Sullivan study provides a comprehensive analysis of the world cancer assay markets. By identifying emerging technology trends and supplying
strategic recommendations, this research allows your company to optimize revenues within this burgeoning field.
Human Genome Project Drives Industry Developments
The Human Genome Project has generated a tremendous amount of information regarding the makeup and structure of the human genome—the implications of which are incredible for the future of medicine in the areas of
diagnosis, prognosis, and treatment of cancer, states the study's author. Completion of the initial mapping of the human genome is a significant accomplishment, laying the initial groundwork for further research.
Results of the Human Genome Project only serve as background knowledge for deciphering the information obtained. Attention is now focused on the area of functional genomics, and identifying specific gene purpose and expression levels as it relates to the disease, which is expected to positively influence market growth.
Less Invasive Procedures Encourage Genetic Testing
Genetic testing serves as an alternative to traditional procedures, providing more informative results and less invasive procedures. For example, testing for cervical cancer usually involves a Pap test, which is then examined for cellular changes and often followed by a colonoscopy, biopsy, or surgery. PAP tests often yield false-negative results or fail altogether. Genetic testing for cervical cancer generates a greater degree of accuracy and only recommends invasive, costly follow-up procedures when the test indicates a high risk of cancer, says the author.
This Frost & Sullivan research provides the most up-to-date intelligence on the world cancer assays markets, enabling participants to implement effective business strategies for future success.
Additional Information
Market Participants
Affymetrix, Inc.
BD Biosciences Clontech
Cambio, Inc.
Cytocell, Ltd.
Digene Corporation
Genzyme Corporation
Myriad Genetics, Inc.
Ventana Medical Systems, Inc.
Vysis, Inc.
Related Companies
Agilent Technologies
Corning, Inc.
DiagnoCure, Inc.
Exact Sciences Corporation
Incyte Genomics, Inc.
Laboratory Corporation of America Holdings
Millenium Pharmaceuticals, Inc.
Nanogen, Inc.
Quest Diagnostics, Inc.
ResGen/Invitrogen Corporation
Customers who bought this item also bought
DNA Sequencing - Technologies, Markets and Companies
Biochips and Microarrays - Technologies, Markets and Companies
Cytogenetics - Technologies, Markets and Companies
Microarray Markets
Polymerase Chain Reaction (PCR): Products/Tools - A Global Market Watch, 2009-2015
European Next Generation Sequencing Markets
Biochips - Products, Applications, Technologies and End-Use Markets Growth Analysis, 2009-2015
Molecular Cytogenetics - Global Strategic Business Report
Genomics, Proteomics and Metabolomics in Diagnostics: Market Landscape, Innovative Technologies and Future Outlook
Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015)
|
|
|
|
